Nygren I, Antonova K, Mattsson P, Askmark H
Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden.
Acta Neurol Scand. 2005 Mar;111(3):180-4. doi: 10.1111/j.1600-0404.2005.00384.x.
To determine whether sales statistics for riluzole can be used as a marker for the prevalence of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) in Sweden.
A questionnaire was sent to all neurological units in Sweden asking about the numbers of patients with ALS/MND and whether these patients were treated with riluzole. Sales statistics for riluzole were obtained from the 906 public pharmacies and 89 hospital pharmacies in Sweden.
Eighty percent of the neurological units answered the questionnaire. The estimated prevalence in September 2003 from the questionnaire was 5.4/100,000 inhabitants. The sales expressed in defined daily dose/100,000 inhabitants/day was 3.8. For the counties the correlation between these two parameters was 0.83.
Estimated prevalence is highly correlated with sales statistics for riluzole. Riluzole sales statistics could be used as a crude marker for the prevalence of ALS/MND in Sweden.
确定利鲁唑的销售统计数据是否可作为瑞典肌萎缩侧索硬化症(ALS)/运动神经元病(MND)患病率的一个指标。
向瑞典所有神经科单位发送了一份问卷,询问ALS/MND患者的数量以及这些患者是否接受利鲁唑治疗。利鲁唑的销售统计数据来自瑞典的906家社会药房和89家医院药房。
80%的神经科单位回复了问卷。根据问卷估算,2003年9月的患病率为每10万居民中有5.4例。以限定日剂量/每10万居民/天表示的销售量为3.8。对于各郡而言,这两个参数之间的相关性为0.83。
估算的患病率与利鲁唑的销售统计数据高度相关。利鲁唑销售统计数据可作为瑞典ALS/MND患病率的一个粗略指标。